Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.33 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24027292 | 0.83 | HTT (0.37) | HTTNEU4NEU3GPR88 | |
| SCHEMBL20650987 | 0.72 | P2RX7 (0.47) | — | |
| SCHEMBL28711026 | 0.71 | ADORA3 (0.34) | ADORA3ADORA2AADORA1 | |
| SCHEMBL12092341 | 0.71 | DPP4 (0.36) | ADORA3ADORA2AADORA1 | |
| SCHEMBL3581966 | 0.71 | — | — | |
| SCHEMBL22567172 | 0.69 | — | — | |
| SCHEMBL3581963 | 0.69 | — | — | |
| SCHEMBL17678394 | 0.69 | GGPS1 (0.37) | ADORA2AADORA1 | |
| SCHEMBL23974517 | 0.69 | CYP19A1 (0.54) | — | |
| SCHEMBL10025991 | 0.68 | GGPS1 (0.36) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | LRRK2, PARK7, BRCA1 | HTT 342/4885NEU4 3672/4885NEU3 3225/4885 |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, BRCA1 | HTT 293/4885NEU4 3723/4885NEU3 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.